InflaRx Announces Financial Results and Business Updates for Q2 2025

JENA, Germany — August 7, 2025 — Leads & Copy — InflaRx N.V. (Nasdaq: IFRX) reported its financial results for the three months ended June 30, 2025, alongside a business update. The company anticipates Phase 2a data for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) by late September to early November 2025.

Staidson BioPharmaceuticals announced favorable Phase 1/2 data for the InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV), with Phase 3 study initiation expected. InflaRx is progressing toward unblinding the stopped Phase 3 pyoderma gangrenosum (PG) trial for data analysis later this year. Enrollment has started in the BARDA-funded JUST BREATHE Phase 2 platform clinical trial, assessing vilobelimab and other therapeutics for acute respiratory distress syndrome (ARDS). As of June 30, 2025, InflaRx held €53.7 million in cash, equivalents, and marketable securities, estimating sufficient funds for planned operations into 2027, with a review to potentially prioritize INF904.

Prof. Niels C. Riedemann, CEO of InflaRx, highlighted the potential of INF904 as an oral C5aR inhibitor for unmet needs in inflammatory diseases.

Select recent highlights and business update:

INF904 Phase 2a Trial: Topline results from the ongoing Phase 2a basket study in HS and CSU are expected by the end of September to early November. The data will include primary endpoints of pharmacokinetics (PK) and safety and also will include key clinical benefit endpoints after 4 weeks of treatment.
GOHIBIC (vilobelimab) for ARDS: In June 2025, BARDA announced enrollment of the first patient in the JUST BREATHE Phase 2 platform clinical trial.
Vilobelimab for pyoderma gangrenosum (PG): In May 2025, InflaRx announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in PG recommended that the trial be stopped due to futility.
Development progress with anti-C5a antibody BDB-001 by collaborator Staidson BioPharmaceuticals: In July 2025, Staidson BioPharmaceuticals announced that a multicenter, randomized, open-label, placebo-controlled Phase 1/2 study met its primary efficacy endpoint.

Dr. Thomas Taapken, CFO of InflaRx, noted the company’s strong financial position and cash runway into 2027.

Financial Highlights – 2Q 2025:

Revenue: For the six months ended June 30, 2025, we realized €39 thousand in revenues from sales of GOHIBIC (vilobelimab).
Cost of sales: Cost of sales during the six months ended June 30, 2025 amounted to €2.4 million, primarily due to higher inventory write-downs of €2.4 million.
Sales and marketing expenses: Sales and marketing expenses incurred for the six months ended June 30, 2025 decreased by €0.8 million compared to the six months ended June 30, 2024 to €2.5 million.
Research and development expenses: Research and development expenses incurred for the six months ended June 30, 2025 decreased by €3.1 million to €14.2 million compared to the six months ended June 30, 2024.
General and administrative expenses: General and administrative expenses incurred for the six months ended June 30, 2025 increased by €1.5 million to €8.3 million, compared to the six months ended June 30, 2024.
Other income: Other income for the six months ended June 30, 2025 amounted to €1.5 million, compared to €53 thousand for the six months ended June 30, 2024.
Net financial result: Net financial result decreased by €1.2 million to a gain of €3.2 million for the six months ended June 30, 2025, from a gain of €4.4 million for the six months ended June 30, 2024.
Net loss: We incurred a net loss of €23.0 million, or €0.35 per ordinary share, during the six months ended June 30, 2025, compared to €23.5 million, or €0.40 per ordinary share, in 2024.
Liquidity and capital resources: As of June 30, 2025, our total funds available amounted to approximately €53.7 million.
Net cash used in operating activities: Net cash used in operating activities decreased to €21.6 million in the six months ended June 30, 2025, from €27.0 million in the six months ended June 30, 2024.
Net cash from financing activities: Net cash from financing activities increased by €27.1 million in the six months ended June 30, 2025, compared to the six months ended June 30, 2024, due to a public offering of ordinary shares and pre-funded warrants in the six months ended June 30, 2025.